Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
List view / Grid view
Filter the results
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
Chinese hamster ovary (CHO) cell lines are a firm favourite with biologics companies because of the extensive developmental work undertaken in recent decades. In this article, Junrui Li divulges how CRISPR technology is now being employed to further enhance productivity.